Biogen Inc (BIIB) Gross Profit Margin starting from the first quarter 2026 to first quarter 2025, Profitability Trends and Ranking, Fundamental Ratios - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Gross Margin
• EBITDA Margin
• Operating Margin
• Net Margin
• Pre-Tax Margin
• Effective Tax Rate
• Free Cash Flow Margin
• Cash Flow Margin
Biogen Inc   (NASDAQ: BIIB)


Biogen Inc 's Gross Profit Margin by quarter

Trends, Rankings, Statistics


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

BIIB Gross Profit Margin (Mar 31 2026)
Q1 		(Dec 31 2025)
Q4 		(Sep 30 2025)
Q3 		(Jun 30 2025)
Q2 		(Mar 31 2025)
Q1
Y / Y Revenue Change 1.93 %
Seq. Revenue Change 8.7 %
Revenue In Millions $2,477.80
Gross Profit Margin 73.32 %
Gross Profit Margin Total Ranking # 892
Gross Profit In Millions $1,816.80
Y / Y Gross Profit Change 0.84 %
Seq. Gross Profit Change 1.84 %


Commenting First Quarter 2026 Gross Profit Margin
Biogen Inc has managed to improve its Revenue sequentially to $2,477.80 millions by 8.7 % faster than Gross Profit increase of 1.84 % to $1,816.80 millions, this led to contraction in Gross Profit Margin to 73.32 %, below company average.


Observing first quarter 2026 results within Biotechnology & Pharmaceuticals industry 19 other companies have achieved higher Gross Profit Margin. While Gross Profit Margin overall ranking has deteriorated relative to the three months before, from 751 to 892.
Learn about Gross Margin
BIIB's Gross Profit Margin first quarter 2026 Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 20
Healthcare Sector # 156
Overall # 886

Gross Profit Margin Statistics
High Average Low
91.85 % 83.01 % 6.8 %
(Dec. 31, 2006)   (Dec. 31, 2003)


BIIB Gross Income Trends • More of BIIB's Profitabilty Ratios • BIIB Stock Quotes and Charts


Other Gross Profit Margin Profitability Ratios
BIIB's Cumulative Gross Profit Margin
Biotechnology & Pharmaceuticals Industry Gross Profit Margin Trends and Statistics
Healthcare Sector Gross Profit Margin Statistics
Gross Profit Margin Profitability Trends for overall market
BIIB's Gross Profit Margin Profitability versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Gross Profit Margin
Lowest Ranking Gross Profit Margin
Gross Profit Margin Profit Margin for BIIB's Competitors
Gross Profit Margin Profit Margin for Biogen Inc 's Suppliers
Gross Profit Margin Profit Margin for BIIB's Customers

You may also want to know
BIIB's Annual Growth Rates BIIB's Profitability Ratios BIIB's Asset Turnover Ratio BIIB's Dividend Growth
BIIB's Roe BIIB's Valuation Ratios BIIB's Financial Strength Ratios BIIB's Gross Profit Growth
BIIB's Roa BIIB's Inventory Turnover Ratio BIIB's Growth Rates BIIB's Dividend Comparisons


Companies with similar Gross Profit Margin in the quarter ending Mar 31 2026, within Biotechnology & Pharmaceuticals Industry Gross Profit MarginMar 31 2026 MRQ Gross ProfitMar 31 2026 MRQ Revenue
Immunocore Holdings Plc  99.59 %$ 106.243  Millions$ 106.677  Millions
Immunitybio inc   99.46 %$ 43.968  Millions$ 44.206  Millions
Invivyd Inc   98.78 %$ 13.576  Millions$ 13.744  Millions
Neurocrine Biosciences Inc   98.31 %$ 800.700  Millions$ 814.500  Millions
Exelixis Inc   96.73 %$ 590.859  Millions$ 610.812  Millions
Biocryst Pharmaceuticals Inc   96.56 %$ 151.036  Millions$ 156.413  Millions
Tarsus Pharmaceuticals Inc   94.20 %$ 152.658  Millions$ 162.054  Millions
Maze Therapeutics Inc   91.04 %$ 18.208  Millions$ 20.000  Millions
Protalix Biotherapeutics inc   87.77 %$ 29.623  Millions$ 33.750  Millions
Pelthos Therapeutics Inc   84.66 %$ 9.233  Millions$ 10.906  Millions
Ginkgo Bioworks Holdings Inc   84.09 %$ 16.376  Millions$ 19.474  Millions
Aim Immunotech Inc   81.82 %$ 0.018  Millions$ 0.022  Millions
Zeo Scientifix Inc   79.62 %$ 2.055  Millions$ 2.581  Millions
Gilead Sciences Inc   79.24 %$ 5,515.000  Millions$ 6,960.000  Millions
Halozyme Therapeutics Inc   78.97 %$ 297.470  Millions$ 376.708  Millions
Novavax inc   78.00 %$ 108.819  Millions$ 139.514  Millions
X4 Pharmaceuticals Inc  77.92 %$ 2.110  Millions$ 2.708  Millions
Humacyte Inc   77.41 %$ 6.982  Millions$ 9.020  Millions
Adaptive Biotechnologies Corporation  73.60 %$ 52.166  Millions$ 70.874  Millions
Biogen Inc   73.32 %$ 1,816.800  Millions$ 2,477.800  Millions
Vericel Corporation  72.00 %$ 49.266  Millions$ 68.425  Millions
Adma Biologics Inc   70.99 %$ 80.750  Millions$ 113.750  Millions
Coherus Oncology inc   69.02 %$ 8.496  Millions$ 12.310  Millions
Amgen Inc   68.16 %$ 5,874.000  Millions$ 8,618.000  Millions
Bio techne Corp  66.91 %$ 208.288  Millions$ 311.288  Millions
Elutia Inc   64.31 %$ 1.802  Millions$ 2.802  Millions
Xtant Medical Holdings Inc   59.94 %$ 11.971  Millions$ 19.971  Millions
Repligen Corp  55.74 %$ 108.284  Millions$ 194.255  Millions
Twist Bioscience Corporation  51.59 %$ 57.122  Millions$ 110.715  Millions
Champions Oncology Inc   50.79 %$ 7.027  Millions$ 13.836  Millions




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.